Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Characteristics of Patients with Parkinson’s Disease and Cognitive Impairment
Movement Disorders
P11 - Poster Session 11 (8:00 AM-9:00 AM)
3-011
To understand characteristics of patients with Parkinson’s disease (PD) prior to a new diagnosis of cognitive impairment (CI; memory loss/mild cognitive impairment/dementia or dementia treatment initiation).
Characterizing patients with PD newly diagnosed with CI using real world data is important to better understand the natural history and unmet needs of these individuals.
In this retrospective cohort study, patients with PD newly diagnosed with CI (2010-2014) were identified using administrative claims data. They were matched (1:1) on age and gender with patients with PD but without CI (controls). Patient characteristics three years before date of first CI diagnosis or first prescription for dementia (index) were compared to those of controls using Chi-square tests, t-tests, and Wilcoxon rank-sum tests, as appropriate. Factors predicting a new CI diagnosis were identified using logistic regression. P-values <0.05 were considered statistically significant.
Patients with CI (N=2711) and controls were, on average, ~75 years old, male (~53%), white (~85%), living in urban areas (~68%), and enrolled in Medicare Advantage Prescription Drug plans (MAPD; ~98%). Comorbidity burden for patients with CI increased over the three years before index and was higher than controls during the year before index (P<0.001). Compared to controls, more patients with CI had congestive heart failure, peripheral vascular disease, cerebrovascular disease (CVD), and chronic obstructive pulmonary disease during the year before index (all, P<0.05). During each year before index, more patients with CI were on PD medications than controls (45.4%-66.3% versus 35.3-48.7%; all, P<0.001). Enrollment in MAPD versus commercial (odds ratio [OR]=1.60), dual Medicare/Medicaid eligibility (OR=1.36), CVD (OR=1.24), and higher PD medication use (OR=1.46) were associated with a new CI diagnosis (all, P<0.05).
In patients with PD newly diagnosed with CI, comorbidity burden increases over time and peaks just before CI diagnosis. More research is needed to understand the relationship between CI and CVD.
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Leanne Munsie Leanne Munsie has received personal compensation for serving as an employee of Eli Lilly and Company. Leanne Munsie has received stock or an ownership interest from Eli Lilly and Company.
No disclosure on file
Lee Wilson No disclosure on file
No disclosure on file
Kevin M. Biglan, MD (Eli Lilly) Dr. Biglan has received personal compensation for serving as an employee of Eli Lilly. Dr. Biglan has received stock or an ownership interest from Eli Lilly.